Special Issue Information

Dear Colleagues,

Chemotherapy is not always effective enough and can have significant side effects; therefore, it is not indicated in some categories of patients (especially the elderly) due to its toxicities and their comorbidities. These are arguments that led to the emergence and development of immunotherapy. Its results have radically improved the evolution of many oncohematological diseases, and this trend continues in parallel with the improvement of production technologies and the expansion of the product range. Such types of immunotherapies are naked or ordinary monoclonal antibodies, antibody-drug conjugates, bi-specific T-cell engagers, adoptive cell transfer, including chimeric antigen receptor T-cells and chimeric antigen receptor-engineered natural killer cells, and immune checkpoint inhibitors. Unfortunately, the increasing use of immunotherapy and immunochemotherapy has dramatically increased the frequency of side effects, including life-threatening clinical manifestations and significant immunosuppression (with risk of infection or a new neoplasm).

Finding a balance between targeted immuno-chemotherapy and protecting the patient's immune system is the key to obtaining good results with the lowest possible risk of infections and secondary neoplasms.

This Special Issue, “Immunotherapy of Hematological Malignancies: The State of the Art", aims to provide an overview of current and developing immunotherapy treatments, endeavoring to give some answers to the many questions and concerns that exist and to facilitate the emergence of new research directions to improve therapeutic results.

Prof. Dr. Anca Colita Prof. Dr. Romeo Gabriel Mihaila

https://www.mdpi.com/journal/jcm/special_issues/I7HONV3B89#info